91603-25-7

Upstream product

• 828291-16-3 E/Z-<2(RS)>-2-Methyl-N-(R-α-methylbenzyl)-cyclohexaneimine 
• 195251-76-4 E/Z-<2(RS)>-2-Methyl-N-(S-α-methylbenzyl)-cyclohexaneimine 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 583-60-8 2-Methylcyclohexanone 
• 73739-21-6 (R,Z)-N-(2-methylcyclohexylidene)-1-phenylethaneamine 

Downstream Products

• 10049-61-3 (+)-cis-2-Methyl cyclohexylamine hydrochloride 
• 10049-61-3 (-)-cis-2-Methyl cyclohexylamine hydrochloride 
• 1263419-22-2 4-((1R,2S)-2-methylcyclohexylamino)-6-nitropyrrolo[1,2-b]pyridazine-3-carbonitrile 
• 1263419-23-3 4-((1R,2S)-2-methylcyclohexylamino)-6-nitropyrrolo[1,2-b]pyridazine-3-carboxamide 
• 1263419-24-4 6-amino-4-((1R,2S)-2-methylcyclohexylamino)pyrrolo[1,2-b]pyridazine-3-carboxamide 
• 1263419-13-1 4-((1R,2S)-2-methylcyclohexylamino)pyrrolo[1,2-b]pyridazine-3-carboxamide 
• 1263420-10-5 4-((1R,2S)-2-methylcyclohexylamino)pyrrolo[1,2-b]pyridazine-3-carbonitrile 
• 79389-41-6 (1R,2S)-(+)-cis-2-Methyl-cyclohexanamin-hydrochlorid 

Relevant academic research and scientific papers

PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS

The invention provides compounds of formula l: ( I ) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I.

ASYMMETRIC SYNTHESIS OF CIS-2-SUBSTITUTED CYCLOHEXANAMINES WITH HIGHT OPTICAL PURITY

Asymmetric reductive amination of racemic 2-substituted cyclohexanones (R= methyl, ethyl, phenyl, benzyl) using optically active 1-phenyl-ethylamines yields optically active cis-cyclohexanamines.